BioCentury
ARTICLE | Company News

Valeant Pharmaceuticals, Sanofi deal

July 18, 2011 7:00 AM UTC

Valeant will acquire Sanofi's Dermik dermatology unit for $425 million in cash. Dermik, which markets therapeutic and aesthetic dermatology products mainly in the U.S. and Canada, had total 2010 revenue of about $240 million. Valeant said the acquisition will expand its dermatology franchise in the U.S. and Canada. Sanofi said the move is in line with its strategy to reallocate resources in North America to high growth areas, including diabetes, cancer, atrial fibrillation and consumer healthcare. ...